Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Auto-injector (AI) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants

NCT03707717
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 55 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects

NCT02675023
View directory record Official record
Conditions
Healthy
Interventions
M923
Biological
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
603 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 8, 2026, 5:31 PM EDT
Active, not recruiting Phase 2 Interventional

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365
View directory record Official record
Conditions
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

NCT03766685
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

NCT02996019
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Etrolizumab, Auto-Injector (AI), Prefilled Syringe With Needle Safety Device (PFS-NSD)
Drug · Device
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Sep 8, 2026, 5:31 PM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

NCT04333147
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Otilimab (GSK3196165), csDMARD(s)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
79
States / cities
Anniston, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

NCT03415178
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY), Atorvastatin, Rosuvastatin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
13
States / cities
Los Angeles, California • Jacksonville, Florida • Ponte Vedra, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
Biological · Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

NCT05405985
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional

To Assess the Patients' Ability to Self-Administer Fasinumab

NCT03491904
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab AI, Fasinumab PFS
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
Gilbert, Arizona • Glendale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17

NCT04295356
View directory record Official record
Conditions
Healthy
Interventions
CT-P17
Biological
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

NCT06471361
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
New Haven, Connecticut • Tampa, Florida • Columbia, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants

NCT05283681
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Grayslake, Illinois • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

NCT04109976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Boise, Idaho • Lexington, Kentucky • Baton Rouge, Louisiana + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

NCT03560739
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ofatumumab with PRF, ofatumumab with AI
Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Usability of an AI for M923 in Subjects With Moderate to Severe RA

NCT02722044
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
M923, Autoinjector
Biological · Device
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Detroit, Michigan • Greensboro, North Carolina • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 8, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

NCT05533801
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lecanemab
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 8, 2026, 5:31 PM EDT